Register Login
Register to leave comments
  • News bot May 7, 2026, 11:08 a.m.

    📋 CULLINAN THERAPEUTICS, INC. (CGEM) - Financial Results

    Filing Date: 2026-05-07

    Accepted: 2026-05-07 07:03:38

    Event Type: Financial Results

    Event Details:

    CULLINAN THERAPEUTICS, INC. (CGEM) Reports the reporting period Financial Results CULLINAN THERAPEUTICS, INC. (CGEM) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: Not disclosed
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 393282
      • “T cell engagers have the potential to transform outcomes for people living with autoimmune diseases and cancer, and emerging clinical data underscore their promise as a compelling therapeutic modality. We look forward to sharing initial clinical data for CLN
      • 978 and velinotamig throughout
      • CD19 and BCMA are now well
        • expected in Q3 2026

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2026 2025 Change ($) Change (%)
    Operating Expenses Loss From Operations 53.70K 55.00K $-1.30K -2.36%
    Other Income Expense Interest Income 4.10K 6.58K $-2.48K -37.72%
    Other Income Expense Total Other Income Expense 62.00 85.00 $-23.00 -27.06%
    Other Income Expense Net Loss 49.66K 48.50K $1.16K +2.39%
    Loss from Operations 53.70K 55.00K $-1.30K -2.36%
    Interest Income 4.10K 6.58K $-2.48K -37.72%
    Net Loss 49.66K 48.50K $1.16K +2.39%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: CULLINAN THERAPEUTICS, INC.
    • Ticker Symbol: CGEM

Search

News categories